Full-Life Technologies is a global leader in the field of radiotherapeutics, focusing on the development and production of radiopharmaceuticals. The company employs a unique approach by attaching radionuclides to targeting vectors, such as peptides, small molecules, and single-domain antibodies, which allows for precise delivery of therapeutic agents directly to tumors. This innovative method enhances the efficacy of cancer treatments by ensuring that the therapeutic payload is concentrated at the site of the tumor, thereby minimizing damage to surrounding healthy tissues. Full-Life's pipeline includes a range of differentiated programs targeting various cancer indications, showcasing their commitment to advancing cancer care through cutting-edge technology.

To support its strategic goals, Full-Life Technologies is establishing state-of-the-art manufacturing facilities designed to produce radiopharmaceutical drug products that comply with global Good Manufacturing Practice (GMP) standards. The company also prioritizes logistics by collaborating with leading supply-chain partners to ensure timely delivery of its products to patients around the world. This comprehensive approach not only addresses the growing clinical demand for innovative therapies but also reinforces Full-Life's position as a key player in the radiopharmaceutical market, dedicated to improving patient outcomes through advanced therapeutic solutions.

China

Full-Life Technologies Limited (“Full-Life”) is a fully integrated global radiopharmaceutical company with operations in Europe and China.

Full-Life Technologies

Company Details